(Yicai Global) Nov. 26 -- Huadong Medicine will provide a cash injection for its newly acquired British aesthetics tech firm Sinclair Pharma to explore foreign markets, including China and the US.

Huadong's board meeting agreed to give no more than CNY400 million (USD57.6 million) to Sinclair to meet the demand of capital for its operations as well as expansion into the global market, the Shanghai-based drugmaker said in a statement on Nov. 23. 

London-based Sinclair has started to prepare its entrance to China and the US markets with registration procedures. All of its products, including Silhouette reabsorbable sutures and Ellanse dermal fillers, are expected to hit the Chinese market in 2020, the statement added. 

Sinclair's products will complement Huadong's Yvoire series of hyaluronic acid dermal fillers and help Huadong to develop and promote new products. 

Huadong offered GBP169 million (USD217 million) in August to acquire all of Sinclair's shares. The transaction was completed in September.

Editor: Emmi Laine